MET and non-small cell lung carcinoma: Furthermore, xenograft tumor analysis revealed that c-Met deficiency extended the survival duration of mice, underscoring the potential prognostic value of c-Met in predicting osimertinib therapeutic sensitivity and highlighting it as a promising therapeutic target for combating drug resistance in NSCLC.